Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 1

Status

Unknown 7Recruiting 6Not yet recruiting 6Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Genitourinary 1

Conditions

Stomach Neoplasms 2Prostatic Neoplasms 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × SHR-1701 × Clear all
NCT07451795 2026-04-30

SHARP

Fudan University

Phase 2 Recruiting
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT07294664 2026-04-16

PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Recruiting
78 enrolled
Gastrointestinal

Advanced Gastric Cancer

NCT05671822 2026-02-12

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2 Recruiting
258 enrolled
Gastrointestinal

HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

NCT07311408 2025-12-31

SHR-2554

China Medical University, China

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07175220 2025-11-18

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
351 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡